Current study was conducted to identify constituents of Taxus wallichiana Zucc. that might be
responsible for its folk use in anti-inflammatory conditions. Taxusabietane A was isolated from
the bark extract of Taxus wallichiana Zucc. Taxusabietane A was analyzed for in-vitro and in-vivo
anti-inflammatory activities using Lipoxygenase (LOX) inhibition assay and carrageenaninduced
paw edema model. Taxusabietane A revealed considerable LOX inhibitory activity
with the IC50 value being 57± 0.31. Standard compound Baicalein showed the IC50 value being
22.1± 0.03 μM. Taxusabietane A also showed significant (5 and 10 mg/kg) anti-inflammatory
activity induced by carrageenan. However, this study highlighted the potential of Taxusabietane
A to be further explored as a new lead compound for management of conditions associated with
inflammation.